American Psychiatric Association. (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn., Rev. Washington, DC: American Psychiatric Assocation.
American Psychiatric Association Press. (1992). ICD-10. The International Statistical Classification of Diseases and Related Health Problems: 1 and 2. Washington, DC: American Psychiatric Association Press.
Baiyewu, O.et al. (2002). Cognitive impairment in community-dwelling older Nigerians: clinical correlates and stability of diagnosis. European Journal of Neurology, 9, 573–580.
Barnes, D. E. and Yaffe, K. (2011). The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurology, 10, 819–828.
Bates, C. J., Mansoor, M. A., Pentieva, K. D., Hamer, M. and Mishra, G. D. (2010). Biochemical risk indices, including plasma homocysteine, that prospectively predict mortality in older British people: the National Diet and Nutrition Survey of people aged 65 years and over. The British Journal of Nutrition, 104, 893–899.
Dangour, A. D.et al. (2010). B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review. Journal of Alzheimer's Disease, 22, 205–224.
Deeg, M.et al. (2008). A comparison of cardiovascular disease risk factor biomarkers in African Americans and Yoruba Nigerians. Ethnicity & Disease, 18, 427–433.
Devlin, A. M., Clarke, R., Birks, J., Evans, J. G. and Halsted, C. H. (2006). Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. The American Journal of Clinicial Nutrition, 83, 708–713.
Ferri, C. P.et al. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet, 366, 2112–2117.
Haan, M. N.et al. (2007). Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on aging. The American Journal of Clinical Nutrition, 85, 511–517.
Hackam, D. G. and Anand, S. S. (2003). Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA, 290, 932–940.
Hall, K. S., Gao, S., Emsley, C. L., Ogunniyi, A. O., Morgan, O. and Hendrie, H. C. (2000). Community screening interview for dementia (CSI ‘D’); performance in five disparate study sites. International Journal of Geriatric Psychiatry, 15, 521–531.
Hendrie, H. C.et al. (1988). The CAMDEX: a standardized instrument for the diagnosis of mental disorder in the elderly: a replication with a US sample. Journal of the American Geriatrics Society, 36, 402–408.
Hendrie, H. C.et al. (2001). Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA, 285, 739–747.
Hendrie, H. C., Hall, K. S., Ogunniyi, A. and Gao, S. (2004). Alzheimer's disease, genes, and environment: the value of international studies. Canadian Journal of Psychiatry, 49, 92–99.
Hendrie, H. C.et al. (2006). The development of a semi-structured home interview (CHIF) to directly assess function in cognitively impaired elderly people in two cultures. International Psychogeriatrics, 18, 653–666.
Ho, R. C.et al. (2011). Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. The American Journal of Geriatric Psychiatry, 19, 607–617.
Kim, J. M.et al. (2008). Changes in folate, vitamin B12 and homocysteine associated with incident dementia. Journal of Neurology, Neurosurgery, and Psychiatry, 79, 864–868.
Kivipelto, M.et al. (2009). Homocysteine and holo-transcobalamin and the risk of dementia and Alzheimers disease: a prospective study. European Journal of Neurology, 16, 808–813.
Luchsinger, J. A., Tang, M. X., Shea, S., Miller, J., Green, R. and Mayeux, R. (2004). Plasma homocysteine levels and risk of Alzheimer disease. Neurology, 62, 1972–1976.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology, 34, 939–944.
Morris, J. C.et al. (1989). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology, 39, 1159–1165.
Olayiwola, I. O., Fadupin, G. T., Agbato, S. O. and Soyewo, D. O. (2012). Serum micronutrient status and nutrient intake of elderly Yoruba people in a slum of Ibadan, Nigeria. Public Health Nutrition, 1–7.
Ozarda, Y., Sucu, D. K., Hizli, B. and Aslan, D. (2009). Rate of T alleles and TT genotype at MTHFR 677C->T locus or C alleles and CC genotype at MTHFR 1298A->C locus among healthy subjects in Turkey: impact on homocysteine and folic acid status and reference intervals. Cell Biochemistry and Function, 27, 568–577.
Plassman, B. L., Williams, J. W. Jr., Burke, J. R., Holsinger, T. and Benjamin, S. (2010). Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Annals of Internal Medicine, 153, 182–193.
Ravaglia, G.et al. (2008). Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. Journal of the American Geriatrics Society, 56, 51–58.
Seshadri, S.et al. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. The New England Journal of Medicine, 346, 476–483.
Unverzagt, F. W.et al. (2001). Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology, 57, 1655–1662.
Unverzagt, F. W.et al. (2011). Incidence and risk factors for cognitive impairment no dementia and mild cognitive impairment in African Americans. Alzheimer Disease and Associated Disorders, 25, 4–10.
Wald, D. S., Kasturiratne, A. and Simmonds, M. (2011). Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers & Dementia, 7, 412–417.